
{
  "Company Overview": {
    "Name": "Indegene Ltd",
    "Sector": "Healthcare",
    "Industry": "Miscellaneous",
    "Business Description": "Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations.  It is a digital-first healthcare and technology company that helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market.  The company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.",
    "Market Position": "Part of Nifty MidSmallcap 400, BSE SmallCap, BSE IPO, BSE Allcap, Nifty Smallcap 250, Nifty 500 Multicap 50:25:25, Nifty Total Market, BSE Healthcare, Nifty 500"
  },
  "Financial Metrics": {
    "Market Cap": "₹ 14,062 Cr.",
    "Current Price": "₹ 588",
    "High/Low": "₹ 737 / ₹ 469",
    "Stock P/E": "37.9",
    "Book Value": "₹ 98.6",
    "Dividend Yield": "0.00 %",
    "ROCE": "29.0 %",
    "ROE": "26.9 %",
    "Face Value": "₹ 2.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further analysis from Balance Sheet data.
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [632, 608, 636, 673, 673, 676, 687],
      "Expenses": [535, 511, 515, 524, 534, 548, 561],
      "Operating Profit": [97, 97, 121, 149, 139, 129, 126],
      "OPM %": ["15%", "16%", "19%", "22%", "21%", "19%", "18%"],
      "Other Income": [13, 28, 12, 13, 26, 22, 21],
      "Interest": [12, 13, 12, 12, 12, 12, 4],
      "Depreciation": [20, 20, 20, 18, 18, 20, 19],
      "Profit before tax": [79, 92, 101, 132, 134, 120, 124],
      "Tax %": ["38%", "26%", "25%", "25%", "29%", "27%", "26%"],
      "Net Profit": [49, 68, 75, 99, 95, 88, 92],
      "EPS in Rs": [2.20, 3.08, 3.38, 4.45, 4.26, 3.67, 3.83]
    },
    "Annual Results": {
      "Sales": [553, 643, 966, 1665, 2306, 2590, 2710],
      "Expenses": [511, 499, 736, 1378, 1910, 2084, 2167],
      "Operating Profit": [42, 144, 230, 287, 396, 505, 543],
      "OPM %": ["8%", "22%", "24%", "17%", "17%", "20%", "20%"],
      "Other Income": [7, -102, -3, -21, 58, 79, 83],
      "Interest": [6, 9, 7, 6, 31, 49, 40],
      "Depreciation": [17, 19, 26, 33, 60, 76, 76],
      "Profit before tax": [26, 14, 195, 226, 363, 459, 510],
      "Tax %": ["45%", "191%", "23%", "28%", "27%", "27%", null],
      "Net Profit": [14, -12, 149, 163, 266, 337, 373],
      "EPS in Rs": [89.98, -40.20, 951.96, 937.73, 11.99, 15.14, 16.21],
      "Dividend Payout %": ["0%", "0%", "0%", "0%", "0%", "0%", null]
    },
    "Balance Sheet Highlights": {
      "Equity Capital": [0.31, 0.31, 0.31, 0.35, 44, 44, 48],
      "Reserves": [73, -105, 324, 764, 1020, 1385, 2312],
      "Borrowings": [147, 483, 51, 66, 502, 490, 88],
      "Other Liabilities": [108, 222, 220, 524, 638, 627, 576],
      "Total Liabilities": [329, 600, 596, 1353, 2204, 2546, 3024],
      "Fixed Assets": [104, 119, 86, 138, 664, 646, 632],
      "CWIP": [0, 0, 0, 0, 0, 0, 0],
      "Investments": [0, 13, 0, 120, 614, 796, 917],
      "Other Assets": [225, 468, 510, 1096, 926, 1103, 1475],
      "Total Assets": [329, 600, 596, 1353, 2204, 2546, 3024]
    },
    "Cash Flow Summaries": {
      "Cash from Operating Activity": [65, 22, 172, 297, 130, 508, null],
      "Cash from Investing Activity": [-18, -16, -81, -158, -896, -326, null],
      "Cash from Financing Activity": [-21, 136, -132, 233, 333, -66, null],
      "Net Cash Flow": [25, 143, -40, 373, -433, 115, null]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": null,
      "Compounded Sales Growth (5 Years)": "36%",
      "Compounded Sales Growth (3 Years)": "39%",
      "Compounded Sales Growth (TTM)": "12%",
      "Compounded Profit Growth (10 Years)": null,
      "Compounded Profit Growth (5 Years)": "88%",
      "Compounded Profit Growth (3 Years)": "32%",
      "Compounded Profit Growth (TTM)": "26%",
      "Stock Price CAGR (10 Years)": null,
      "Stock Price CAGR (5 Years)": null,
      "Stock Price CAGR (3 Years)": null,
      "Stock Price CAGR (1 Year)": null
    },
    "Liquidity Ratios": null, //Not explicitly provided, needs calculation from Balance Sheet data.
    "Profitability Ratios": {
      "Return on Equity (3 Years)": "29%",
      "Return on Equity (Last Year)": "27%",
      "ROCE (10 Years)": null,
      "ROCE (5 Years)": null,
      "ROCE (3 Years)": null,
      "ROCE (Last Year)": "29%"
    },
    "Valuation Ratios": {
      "P/E Ratio": "37.9",
      "Price to Book": null //Needs calculation
    },
    "Other Ratios": {
      "Debtor Days": [60, 127, 108, 97, 102, 91, null],
      "Inventory Days": null,
      "Days Payable": null,
      "Cash Conversion Cycle": [60, 127, 108, 97, 102, 91, null],
      "Working Capital Days": [23, 64, 53, 16, 45, 40, null]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Syngene Intl.", "CMP": "844.00", "P/E": "73.70", "Mar Cap": "33974.12", "Div Yld": "0.15", "NP Qtr": "106.10", "Qtr Profit Var": "-13.19", "Sales Qtr": "891.00", "Qtr Sales Var": "-2.10", "ROCE": "14.74"},
      {"Name": "Indegene", "CMP": "587.70", "P/E": "37.87", "Mar Cap": "14061.83", "Div Yld": "0.00", "NP Qtr": "91.70", "Qtr Profit Var": "22.27", "Sales Qtr": "686.80", "Qtr Sales Var": "8.04", "ROCE": "29.02"},
      {"Name": "Suven Life Scie.", "CMP": "134.72", "P/E": "2937.89", "Mar Cap": null, "Div Yld": "0.00", "NP Qtr": "-49.64", "Qtr Profit Var": "-146.47", "Sales Qtr": "2.57", "Qtr Sales Var": "-16.01", "ROCE": "-36.37"},
      {"Name": "Vimta Labs", "CMP": "961.90", "P/E": "41.99", "Mar Cap": "2136.70", "Div Yld": "0.21", "NP Qtr": "14.59", "Qtr Profit Var": "112.47", "Sales Qtr": "83.14", "Qtr Sales Var": "29.12", "ROCE": "16.82"},
      {"Name": "Kaya Ltd", "CMP": "370.00", "P/E": "484.61", "Mar Cap": null, "Div Yld": "0.00", "NP Qtr": "-15.67", "Qtr Profit Var": "-147.26", "Sales Qtr": "52.52", "Qtr Sales Var": "3.59", "ROCE": "-80.45"},
      {"Name": "Jeevan Scienti.", "CMP": "50.48", "P/E": "1332.17", "Mar Cap": null, "Div Yld": "79.93", "NP Qtr": "0.25", "Qtr Profit Var": "140.00", "Sales Qtr": "11.40", "Qtr Sales Var": "41.44", "ROCE": "-1.03"},
      {"Name": "Transgene Biotek", "CMP": "7.49", "P/E": "56.75", "Mar Cap": null, "Div Yld": "0.00", "NP Qtr": "-0.07", "Qtr Profit Var": "46.15", "Sales Qtr": "0.06", "Qtr Sales Var": "20.00", "ROCE": "-2.07"}
    ],
    "Median": {
      "CMP": "587.7",
      "P/E": "41.99",
      "Mar Cap": "2937.89",
      "Div Yld": "0.0",
      "NP Qtr": "14.59",
      "Qtr Profit Var": "-13.19",
      "Sales Qtr": "83.14",
      "Qtr Sales Var": "3.59",
      "ROCE": "14.74"
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt.",
      "Company is almost debt free.",
      "Company has delivered good profit growth of 88.5% CAGR over last 5 years",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis." ,
    "Shareholding Pattern": {
      "Jun 2024": {
        "FIIs": "3.79%",
        "DIIs": "3.84%",
        "Public": "92.38%",
        "No. of Shareholders": "2,03,599"
      },
      "Sep 2024": {
        "FIIs": "4.82%",
        "DIIs": "3.17%",
        "Public": "92.01%",
        "No. of Shareholders": "1,51,440"
      },
      "Disclaimer": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
    }
  }
}
